Celgene Corp. (CELG) is expected to report Q1 earnings on Thursday, April 29 before the market open, with a conference call scheduled for 9 am ET. Analysts are looking for EPS of 60c on revenue of ...

Celgene Corporation (CELG) is expected to report Q2 earnings before market open Thursday, July 24, with a conference call scheduled for 9:00 a.m. ET. Analysts are expecting a profit of 35c on revenue ...

Will Celgene Corporation (NASDAQ:CELG) burn you? Here’s some data to help answer that question. To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced the election of John Weiland to its Board of Directors. Mr. Weiland has over 30 years in the healthcare industry and ...

TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced a ...

Celgene Corporation (NASDAQ:CELG) has emerged as the leading treatment provider for blood cancer. The company value has almost doubled in the last year due to rising sales of Revlimid and approval of ...

Celgene is set to release earnings on Thursday before the bell. The big biotech's sales and earnings will obviously be important, but what management says about its pipeline will be equally ...

Celgene 1st-qtr results in line with preliminary figures Celgene posts 1st-qtr net profit of 35 cents/shr Posts profit excluding one-time items of 44 cents/shr Shares rise 2 pct in premarket trading ...

Source: U.S. Army RDECOM via Flickr. What: Shares of biotechnology giant Celgene moved lower on Wednesday by $0.08, or less than 0.1%, to finish at $123.10, despite receiving a substantial price ...

(Reuters) - Biotechnology firm Celgene Corp raised its full-year earnings forecast for the second time in three months after it reported a quarterly profit above analysts' estimates, as its cancer ...

What's happening: After announcing that it would pony up $7.2 billion for multiple sclerosis drug developer Receptos and increasing its long-term guidance, shares in Celgene Corporation shot higher by ...

In a year in which the stock market was relatively flat, biotech blue-chip Celgene was a noted outperformer, having gained 5.5% over the 12 months. 2015 was yet another strong year of growth for the ...